First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion StudyRyan J. Sullivan, Bob T. Li, Jeffrey R. Infante et al.|Cancer Discovery|2017Cited by 418
Immune checkpoint inhibitors for POLE or POLD1 proofreading-deficient metastatic colorectal cancerMargherita Ambrosini, Filippo Pietrantonio, Zoe Goldberg et al.|Annals of Oncology|2024Cited by 73
Deep-Learning Model for Tumor-Type Prediction Using Targeted Clinical Genomic Sequencing DataMadison Darmofal, Quaid Morris, Shalabh Suman et al.|Cancer Discovery|2024Cited by 26
Deep Learning Model for Tumor Type Prediction using Targeted Clinical Genomic Sequencing DataMadison Darmofal, Quaid Morris, Shalabh Suman et al.|medRxiv|2023Cited by 4
Abstract 5440: Deep-learning model for tumor type classification enables enhanced clinical decision support in cancer diagnosisMadison Darmofal, Michael Berger, Shalabh Suman et al.|Cancer Research|2023Cited by 2